Mostrar el registro sencillo del ítem
dc.contributor.author
Díaz, Mariángeles

dc.contributor.author
Ledesma, M. M.
dc.contributor.author
Marcini, T.
dc.contributor.author
Pibuel, Matías Arturo

dc.contributor.author
Poodts, Daniela

dc.contributor.author
Evelson, Pablo Andrés

dc.contributor.author
Moreno, S.
dc.contributor.author
Hajos, Silvia Elvira

dc.contributor.author
Arguello, R. J.
dc.contributor.author
Valacco, Maria Pia

dc.contributor.author
Lompardía, Silvina Laura

dc.date.available
2023-08-25T15:29:13Z
dc.date.issued
2021
dc.identifier.citation
4-Methylumbelliferone induces anti-tumor effects independently of its role as a hyaluronan synthesis inhibitor on human aml cells; 13th International Conference Hyaluronan; Virtual; Estados Unidos; 2021; 1-1
dc.identifier.uri
http://hdl.handle.net/11336/209392
dc.description.abstract
Despite continuous improvement in the treatment for acute myeloid leukemia (AML), newtherapies are still needed to overcome resistance and reduce adverse effects. We previouslyproposed that 4-methylumbelliferone (4MU), known as an inhibitor of hyaluronic acid (HA)synthesis, would be an interesting drug for acute leukemia treatment. Previous results in our lab,showed that 4MU inhibited cell proliferation in a dose-dependent manner in human AML cell lines.Moreover, this drug was able to modulate CD44 expression levels, mitochondrial status and ROSproduction. However, it remains to assess whether the observed effects are explained only by theinhibition of HA synthesis. The aim of this work was to analyze if the anti-tumor activity of 4MUon U937 and THP-1 AML cell lines could be explained by HA synthesis inhibition. Resultsshowed, that both AML cell lines were able to produce significant quantities of AH as assessed byELISA. Surprisingly, at the doses tested in this work 4MU was able to partially inhibit HAsynthesis in THP-1 cells but not in U937 cells. Furthermore, the addition of exogenous HA failedto prevent the effects of 4MU on metabolic activity and cell proliferation in both cell lines,evaluated by XTT and 3H-T uptake, respectively. Moreover, in both cell lines 4MU+HA cotreatment failed to prevent the increase in mitochondrial mass and ROS production such as H2O2and O2.-, which were studied by FC using nonyl acridine orange (NAO), DCF-DA and MitoSoxstaining respectively. These results suggested that there would be 4MU mechanisms that areindependent of HA synthesis inhibition. To delve further into these mechanisms, we conducted aproteomic study in U937 cells after 4MU treatment by nano LC-MS/MS. Data analysis performedwith the free software RStudio resulted in fifteen proteins modulated by 4MU. These proteins weremainly related with cell metabolism signatures, but not directly linked to HA synthesismechanisms. In line with this, we performed a Single Cell Metabolism assay (SCENITH)a whichshowed that 4MU would modulate U937 cellular metabolism by significantly reducing itsglycolytic phenotype and increasing mitochondrial energetics dependency compared to untreatedcondition. Taken together, these results show that independently of its role as a HA synthesisinhibitor, 4MU is able to produce a metabolic switch inhibiting tumor progression in AML cells.We consider that these findings expand the knowledge of 4MU mechanisms of action and openthe possibility for its potential use in AML treatment.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
International Society for Hyaluronian Sciences
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
4-METHYLUMBELLIFERONE
dc.subject
HYALURONAN SYNTHESIS
dc.subject
ACUTE MYELOID LEUKEMIA
dc.subject
PROTEOMICS
dc.subject.classification
Otras Ciencias de la Salud

dc.subject.classification
Ciencias de la Salud

dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD

dc.title
4-Methylumbelliferone induces anti-tumor effects independently of its role as a hyaluronan synthesis inhibitor on human aml cells
dc.type
info:eu-repo/semantics/publishedVersion
dc.type
info:eu-repo/semantics/conferenceObject
dc.type
info:ar-repo/semantics/documento de conferencia
dc.date.updated
2022-11-25T00:26:56Z
dc.journal.pagination
1-1
dc.journal.pais
Estados Unidos

dc.journal.ciudad
Oregon
dc.description.fil
Fil: Díaz, Mariángeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
dc.description.fil
Fil: Ledesma, M. M.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
dc.description.fil
Fil: Marcini, T.. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina
dc.description.fil
Fil: Pibuel, Matías Arturo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
dc.description.fil
Fil: Poodts, Daniela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
dc.description.fil
Fil: Evelson, Pablo Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina
dc.description.fil
Fil: Moreno, S.. No especifíca;
dc.description.fil
Fil: Hajos, Silvia Elvira. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
dc.description.fil
Fil: Arguello, R. J.. Centre National de la Recherche Scientifique; Francia
dc.description.fil
Fil: Valacco, Maria Pia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina
dc.description.fil
Fil: Lompardía, Silvina Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
dc.conicet.rol
Autor

dc.conicet.rol
Autor

dc.conicet.rol
Autor

dc.conicet.rol
Autor

dc.conicet.rol
Autor

dc.conicet.rol
Autor

dc.conicet.rol
Autor

dc.conicet.rol
Autor

dc.conicet.rol
Autor

dc.conicet.rol
Autor

dc.conicet.rol
Autor

dc.coverage
Internacional
dc.type.subtype
Conferencia
dc.description.nombreEvento
13th International Conference Hyaluronan
dc.date.evento
2021-06-14
dc.description.ciudadEvento
Virtual
dc.description.paisEvento
Estados Unidos

dc.type.publicacion
Book
dc.description.institucionOrganizadora
International Society for Hyaluronian Sciences
dc.source.libro
13th International Conference Hyaluronan
dc.date.eventoHasta
2021-06-15
dc.type
Conferencia
Archivos asociados